SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Abrahamsson PA. 1999. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 6: 503519.
  • Bar-Tana J. 2001. Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans. Toxicol Lett 120: 919.
  • Bonkhoff H, Stein U, Remberger K. 1994. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: Simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 25: 4246.
  • Brothman AR, Patel AM, Peehl DM, Schellhammer PF. 1992. Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH). Cancer Genet Cytogenet 62: 180185.
  • Butler R, Mitchell SH, Tindall DJ, Young CY. 2000. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 11: 4961.
  • Deeble PD, Murphy DJ, Parsons SJ, Cox ME. 2001. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21: 84718482.
  • Dennis LK, Resnick MI. 2000. Analysis of recent trends in prostate cancer incidence and mortality. Prostate 42: 247252.
  • Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 93639367.
  • Esquenet M, Swinnen JV, Van Veldhoven PP, Denef C, Heyns W, Verhoeven G. 1997. Retinoids stimulate lipid synthesis and accumulation in LNCaP prostatic adenocarcinoma cells. Mol Cell Endocrinol 136: 3746.
  • Fujiwara T, Horikoshi H. 2000. Troglitazone and related compounds: Therapeutic potential beyond diabetes. Life Sci 67: 24052416.
  • Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. 1999. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279284.
  • Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, Nambiar P, Rosenberg DW, Bronson RT, Edelmann W, Kucherlapati R, Gonzalez FJ, Spiegelman BM. 2002. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 99: 1377113776.
  • Gleason DF. 1988. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr 7: 1518.
  • Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. 2002. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8: 11221128.
  • Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, Rhim JS, Nanus DM, Gudas LJ. 2002. Retinol metabolism and lecithin: Retinol acyltransferase (LRAT) levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res 62: 16541661.
  • Gupta RA, Polk DB, Krishna U, Israel DA, Yan F, DuBois RN, Peek RM, Jr. 2001. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 276: 3105931066.
  • Gupta RA, Sarraf P, Brockman JA, Willson TM, Shappell SB, Raftery LA, Willson TM, Dubois RN. 2003. Peroxisome proliferator-activated receptor γ and transforming growth factor β pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J Biol Chem 278: 74317348.
  • Hartel C, Bein G, Kirchner H, Kluter H. 1999. A human whole-blood assay for analysis of T-cell function by quantification of cytokine mRNA. Scand J Immunol 49: 649654.
  • Hauner H. 2002. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18 (Suppl 2):S10S15.
  • Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW. 1998. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 294: 309321.
  • Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. 2000. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60: 54945498.
  • Hsi LC, Wilson L, Nixon J, Eling TE. 2001. 15-lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. J Biol Chem 276: 3454534552.
  • Hsu JY, Feldman D, McNeal JE, Peehl DM. 2001. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61: 28522856.
  • Iyengar S, Manning S, Shook MF, Olson SJ, Wheeler TM, Gupta RA, Dubois RN, Shappell SB. 2002. Expression of peroxisome proliferato activated receptor gamma (PPARγ) regulated genes in benign and malignant prostate tissue: Correlation with 15-lipoxygenase-2 (15-LOX-2) expression. Am Assoc Cancer Res San Francisco. CA. pp 392393.
  • Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA, Jr., Shappell SB. 2000. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: Correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31: 11461154.
  • Kester HA, Blanchetot C, den Hertog J, van der Saag PT, van der Burg B. 1999. Transforming growth factor-beta-stimulated clone-22 is a member of a family of leucine zipper proteins that can homo- and heterodimerize and has transcriptional repressor activity. J Biol Chem 274: 2743927447.
  • Kletzien RF, Clarke SD, Ulrich RG. 1992. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41: 393398.
  • Kofron M, Demel T, Xanthos J, Lohr J, Sun B, Sive H, Osada S, Wright C, Wylie C, Heasman J. 1999. Mesoderm induction in Xenopus is a zygotic event regulated by maternal VegT via TGFbeta growth factors. Development 126: 57595770.
  • Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. 1998. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 33443352.
  • Lytton B. 2001. Prostate cancer: A brief history and the discovery of hormonal ablation treatment. J Urol 165: 18591862.
  • Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. 1998. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465470.
  • Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. 2000. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97: 1099010995.
  • Murphy GJ, Holder JC. 2000. PPAR-gamma agonists: Therapeutic role in diabetes, inflammation, and cancer. Trends Pharmacol Sci 21: 469474.
  • Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93: 229240.
  • Nakashiro K, Kawamata H, Hino S, Uchida D, Miwa Y, Hamano H, Omotehara F, Yoshida H, Sato M. 1998. Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. Cancer Res 58: 549555.
  • Peehl DM. 2002. Human prostatic epithelial cells. In: FreshneyRI, FreshneyMG, editors. Culture of epithelial cells. 2nd Edn. New York, NY: Wiley-Liss., Inc. pp 159180.
  • Rae FK, Stephenson SA, Nicol DL, Clements JA. 2000. Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer 88: 726732.
  • Rosen ED, Spiegelman BM. 2001. PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 3773137734.
  • Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. 1998. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 10461052.
  • Schmid HP, McNeal JE. 1992. An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am J Surg Pathol 16: 184191.
  • Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. 1999. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155: 235245.
  • Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, Dubois RN. 2001a. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 61: 497503.
  • Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, Olson SJ, Jack GS, Coffey CS, Wheeler TM, Breyer MD, Brash AR. 2001b. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3: 287303.
  • Tang S, Bhatia B, Maldonado CJ, Yang P, Newman RA, Liu J, Chandra D, Traag J, Klein RD, Fischer SM, Chopra D, Shen J, Zhau HE, Chung LW, Tang DG. 2002. Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 277: 1618916201.
  • Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. 1997. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94: 237241.
  • Wang J, Waxman J. 2000. Chemotherapy for prostate cancer. Urol Oncol 5: 9396.
  • Wang X, Reape TJ, Li X, Rayner K, Webb CL, Burnand KG, Lysko PG. 1999. Induced expression of adipophilin mRNA in human macrophages stimulated with oxidized low-density lipoprotein and in atherosclerotic lesions. FEBS Lett 462: 145150.